Kardiovaskuläre Protektion
durch GLP-1-Rezeptor-Agonisten
Cardio-Update 19. August 2021
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 1
Disclosure
• Vortragshonorare: Novo Nordisk, Boehringer Ingelheim
• Beratungshonorare: Boehringer Ingelheim
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 2
Patient 1
• 45 y, m
• 100 kg, 172 cm, BMI 33.8 kg/m²
• Neu DM2, HbA1c 10.5%
• STEMI vor 2 Wochen, 3 GE-KHK
• LV-EF normal
• GFR 70 ml/min/m²
• Art. HTN
Welche Therapie für DM
zusätzlich zu Lifestyle + Metformin
• Lantus 20 E, 1xtgl.
• Humalog zu den Mahlzeiten
• Empagliflozin 10 mg 1x tgl.
• Liraglutid, beg. mit 0.6 mg tgl.
• Dulaglutid 0.75 mg 1x/Woche
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 3
Patientin 2
• 64 y, f
• 80 kg, 166 cm, BMI 29.0 kg/m²
• DM2, HbA1c 7.9%
• PVAK
• GFR 60 ml/min/m²
• Aktuelle Therapie: Metformin, Lantus 40 E, Novo Rapid 4-10 E pro Hauptmahlzeit
• Wie weiter mit der Therapie?
• abwarten
• Lantusdosis steigern
• Novorapiddosis steigern
• NovoRapid stoppen, Start Dapagliflozin
• NovoRapid stoppen, Start
Ozempic (Semaglutid) 1x/Woche
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 4
Physiologie und Pharmakologie
GLP-1-Rezeptor Agonisten
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 5
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 6
Nutrient-induced stimulation of GLP-1 secretion in the L-cell
From: T.D. Müller, …, R.D. DiMarchi, M.H. Tschöp, Glucagon-like peptide 1 (GLP-1),
Molecular Metabolism, Volume 30,
2019,
Pages 72-130, ISSN 2212-8778,
https://doi.org/10.1016/j.molmet.2019.09.010.
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 7
From: T.D. Müller, …, R.D. DiMarchi, M.H. Tschöp, Glucagon-like peptide 1 (GLP-1),
Molecular Metabolism, Volume 30,
2019,
Pages 72-130, ISSN 2212-8778,
https://doi.org/10.1016/j.molmet.2019.09.010.
Wirkungen von GLP-1-RA beim Typ 2 DM
• Senkung der Nüchtern-Glukose
• Senkung des HbA1c
• Senkung des Appetits Reduktion Körpergewicht weitere Verbesserung des Glucose-Metabolismus
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 8
Aktuell verfügbare GLP-1 Analoga
• Exenatide (Byetta, 2x tgl. s.c. )
• Lixisenatide (Lyxumia, 1x tgl. 10 min vor dem Essen).
• Exenatide Depot (Bydureon, 1x /Woche s.c.)
• Liraglutide (Victoza, 1x tgl. s.c.)
• Dulaglutide (Trulicity, 1x/Woche s.c.)
• Semaglutide (Ozempic, 1x/Woche s.c., Rybelsus oral 1x tgl. 3-14 mg)
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 9
Paradigmenwechsel
In der Therapie des DM2
Mikrovaskuläre Endpunkte Makrovaskuläre Endpunkte
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 10
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 11
Naveed Sattar. Circulation. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks, Volume: 139, Issue: 19, Pages: 2228-2237, DOI:
(10.1161/CIRCULATIONAHA.118.037885)
Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks
Findings From the Swedish National Diabetes Registry
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 12
Naveed Sattar. Circulation. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks, Volume: 139, Issue: 19, Pages: 2228-2237, DOI:
(10.1161/CIRCULATIONAHA.118.037885)
Übersterblichkeit durch Typ 2 DM
• Getrieben durch
• CV-Morbidität und Mortalität
• = Makrovaskuläre Komplikationen
• aggressive Therapie der CV-Risikofaktoren
• Statine
• ACE-I / AT1-RA
• Häufige Komorbidität: Adipositas
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 13
Accord Trial
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 14
The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008;358:2545-2559
Original Article
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl.
Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J.
Woerle, M.D., Uli C. Broedl, M.D., Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators
N Engl J Med
Volume 373(22):2117-2128
November 26, 2015
Cardiovascular Outcomes and Death from Any Cause.
Zinman B et al. N Engl J Med 2015;373:2117-2128
GLP-1-RA
Cardiovascular Outcome Trials
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 17
Pfeffer MA et al. N Engl J Med 2015;373:2247-2257.
Lixisenatide
Characteristics of the Patients at Baseline.
Pfeffer MA et al. N Engl J Med 2015;373:2247-2257.
Mean Glycated Hemoglobin Level, According to Study Visit.
Pfeffer MA et al. N Engl J Med 2015;373:2247-2257.
Kaplan–Meier Plot of the First Confirmed Primary End-Point
Event.
Effects of Once-Weekly Exenatide.
Holman RR et al. N Engl J Med ;377:1228-1239
Long Acting Exenatide–CVOT- Trial Outcomes.
Holman RR et al. N Engl J Med ;377:1228-1239
Marso SP et al. N Engl J Med 2016;375:311-322.
Liraglutide - Primary and Exploratory Outcomes.
Marso SP et al. N Engl J Med 2016;375:311-322.
Liraglutide – Leader Trial - Primary and Secondary Outcomes.
Marso SP et al. N Engl J Med 2016;375:1834-1844.
Semaglutide – Once Weekly - Glycated Hemoglobin and Body
Weight.
Marso SP et al. N Engl J Med 2016;375:1834-1844.
Cardiovascular Outcomes.
Marso SP et al. N Engl J Med 2016;375:1834-1844.
Primary and Secondary Cardiovascular and Microvascular
Outcomes.
Original Article
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, M.D., Andreas L. Birkenfeld, M.D., Morten Donsmark, Ph.D., Kathleen Dungan, M.D., M.P.H., Freddy G. Eliaschewitz, M.D., Denise R.
Franco, M.D., Ole K. Jeppesen, M.Sc., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Ofri Mosenzon, M.D., Sue D. Pedersen, M.D., Cees J. Tack, M.D., Mette Thomsen, M.D.,
D.M.Sc., Tina Vilsbøll, M.D., D.M.Sc., Mark L. Warren, M.D., Stephen C. Bain, M.D., for the PIONEER 6 Investigators
N Engl J Med
Volume 381(9):841-851
August 29, 2019
Efficacy Outcomes (In-Trial Observation Period).
Husain M et al. N Engl J Med 2019;381:841-851
Cardiovascular Outcomes.
Husain M et al. N Engl J Med 2019;381:841-851
Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials
Diabetes, Obesity and Metabolism, Volume: 22, Issue: 2, Pages: 203-211, First published: 08 October 2019, DOI:
(10.1111/dom.13888)
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 32
Diabetes, Obesity and Metabolism, Volume: 22, Issue: 2, Pages: 203-211, First published: 08 October 2019, DOI:
(10.1111/dom.13888)
HC Gerstein et al. N Engl J Med 2021. DOI: 10.1056/NEJMoa2108269
Efpeglenatide - Major Cardiovascular and Renal Outcomes.
Praktische Bedeutung
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 34
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 35
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 36
Patient 1
• 45 y, m
• 100 kg, 172 cm, BMI 33.8 kg/m²
• Neu DM2, HbA1c 10.5%
• STEMI vor 2 Wochen, 3 GE-KHK
• LV-EF normal
• GFR 70 ml/min/m²
• Art. HTN
Welche Therapie für DM
zusätzlich zu Lifestyle + Metformin
• Lantus 20 E, 1xtgl.
• Humalog zu den Mahlzeiten
• Empagliflozin 10 mg 1x tgl.
• Liraglutid, beg. mit 0.6 mg tgl.
• Dulaglutid 0.75 mg 1x/Woche
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 37
Patientin 2
• 64 y, f
• 80 kg, 166 cm, BMI 29.0 kg/m²
• DM2, HbA1c 7.9%
• PVAK
• GFR 60 ml/min/m²
• Aktuelle Therapie: Metformin, Lantus 40 E, Novo Rapid 4-10 E pro Hauptmahlzeit
• Wie weiter mit der Therapie?
• abwarten
• Lantusdosis steigern
• Novorapiddosis steigern
• NovoRapid stoppen, Start Dapagliflozin
• NovoRapid stoppen, Start
Ozempic (Semaglutid) 1x/Woche
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 38
Typische UAW
• Übelkeit
• GI-Beschwerden
• Pat. informieren lässt rasch nach
• Dosis langsam steigern
• Anfänglich: kein Alkohol, nicht scharf essen, weniger essen.
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 39
Fazit
• GLP-1-RA senken die kardiovaskuläre Mortalität bei Pat. mit DM2
• An erster Stelle zur pharmakologischen Therapie des DM2 zusammen mit SGLT2
• Wie entscheiden? Faustregel
• HF SGLT2
• Adipositas GLP1-RA
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 40
Outlook
Dual / Triple Receptor Agonists
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 41
Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on the Glycated Hemoglobin Level, Percentage of Patients Who Met Glycated Hemoglobin Level Targets, and Fasting Serum
Glucose Levels.
Frías JP et al. N Engl J Med 2021;385:503-515
Effect of Once-Weekly Tirzepatide, as Compared with Semaglutide, on Body Weight, the Percentage of Patients Who Met Weight-Loss Goals, and the Lipid Profile.
Frías JP et al. N Engl J Med 2021;385:503-515
2021-08-19 Matthias J. Betz, Translational Metabolism, University
Hospital Basel 44